Journal of Literature Pharmacy Sciences

Herpes Simpleks Virüsleri ve Aşı Çalışmaları: Geleneksel Derleme
Herpes Simplex Viruses and Vaccine Studies: A Traditional Review
Deniz Arca ÇAKIRa,b, Terken BAYDARc, Pınar ERKEKOĞLUb,c
aHacettepe Üniversitesi Aşı Enstitüsü, Aşı Çalışmaları ABD, Ankara, Türkiye
bHacettepe Üniversitesi Aşı Enstitüsü, Aşı Teknolojisi ABD, Ankara, Türkiye
cHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Ankara, Türkiye
J Lit Pharm Sci. 2022;11(3):201-12
doi: 10.5336/pharmsci.2022-89865
Article Language: TR
Full Text
ÖZET
 Herpes simpleks virüsleri (HSV), 2500 yıldan uzun süredir hayatımızda olan ve her yıl 23 milyondan fazla yeni vaka ile dünya çapında en sık rastlanılan viral enfeksiyonlara neden olmaktadır. Herpes virüslerinin ayırt edici özelliği, tekrarlayan enfeksiyonlar üretme yetenekleridir. Bu virüslerin neden olduğu enfeksiyonlar, dünya çapında en yaygın viral enfeksiyonlardandır ve yaşam boyu belirli aralıklarla enfeksiyona yol açabilirler. HSV-1 enfeksiyonları, öncelikle dudak ve ağız içi kabarcıklar ve inflamasyon dâhil olmak üzere hafif semptomlarla ilişkilidir. Ancak bazı durumlarda körlük, işitme bozukluğu ve ölümcül ensefalit gibi daha ciddi hastalıklara neden olabilmektedir. HSV-1 nöronal enfeksiyonunun Alzheimer hastalığının patogenezinde rol oynayabileceğine dair artan kanıtlar da bulunmaktadır. Benzer şekilde, HSV-2 enfeksiyonları hafif genital lezyonlara neden olabilmektedir. Ayrıca insan immün yetmezlik virüsü enfeksiyonlarını edinme ve iletme riskini artırabilmektedir. HSV enfeksiyonları, hem doğal hem de adaptif bağışıklığı tetikler. Bu enfeksiyonların spesifik bir tedavisi yoktur. Hafif komplikasyonlar arasında olan yaralar genellikle tedaviye ihtiyaç duyulmaksızın geçmektedir. HSV, dünya çapında yaygın bir enfeksiyon olması, ciddi klinik sonuçları olan yaşam boyu enfeksiyonlara neden olması nedeniyle bu virüse karşı profilaktik ve terapötik aşı geliştirme çalışmaları devam etmektedir. Bugüne kadar alt ünite, canlı zayıflatılmış, replikasyon kusurlu virüs bazlı, nükleik asit temelli birçok aşı geliştirilmiş olmasına rağmen geliştirilen hiçbir aşı beklenilen oranda koruma sağlayamamıştır. Bu geleneksel derlemede, HSV hakkında genel bilgiler verilerek mevcut aşı çalışmaları değerlendirilmiştir

Anahtar Kelimeler: Herpes simpleks virüsü-1; Herpes simpleks virüsü-2; viral enfeksiyon; aşı; aşı geliştirme
ABSTRACT
 Herpes simplex viruses (HSV) have been in our lives for more than 2500 years. It causes the most common viral infections worldwide, with more than 23 million new cases each year. A distinctive feature of herpes viruses is their ability to produce recurrent infections. Infections caused by these viruses are among the most common viral infections worldwide and can lead to infection at certain intervals throughout life. HSV-1 infections are primarily associated with mild symptoms, including blisters and inflammation of the mouth and lips, but in some cases can cause more serious diseases such as blindness, hearing impairment and fatal encephalitis. There is also increasing evidence that HSV-1 neuronal infection may play a role in the pathogenesis of Alzheimer's disease. Similarly, HSV-2 infections can cause mild genital lesions. It may also increase the risk of acquiring and transmitting human immunodeficiency virus infections. HSV infections trigger both innate and adaptive immunity. There is no specific treatment for these infections. Wounds with mild complications usually heal without the need for treatment. As HSV is a common infection worldwide and has serious clinical consequences and causes lifelong infections, prophylactic and therapeutic vaccine development studies are ongoing against this virus. Although many subunit, live attenuated, replication-defective virus-based and nucleic acid-based vaccines have been developed to date, none of the vaccines developed have been able to provide protection at the expected level. In this traditional review, current vaccine studies were evaluated by giving general information about HSV.

Keywords: Herpes simplex virus-1; herpes simplex virus-2; viral infection; vaccine; vaccine development
REFERENCES:
  1. Roizman B, Knipe D, Whitley R. Herpes simplex viruses. In: Knipe D, Howley P, eds. Fields Virology. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p.1823-97.
  2. Beswick TS. The origin and the use of the word herpes. Med Hist. 1962;6(3):214-32. [Crossref]  [PubMed]  [PMC] 
  3. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014;209(3):325-33. [Crossref]  [PubMed] 
  4. Reske A. The innate immune response to HSV-1: glycoprotein mediated activation of dendritic cells. [Doctoral thesis]. London: University College London, Department of Immunology; 2009. Erişim tarihi: 20 Mart 2022. Erişim linki: [Link] 
  5. Lan K, Luo MH. Herpesviruses: epidemiology, pathogenesis, and interventions. Virol Sin. 2017;32(5):347-8. [Crossref]  [PubMed]  [PMC] 
  6. Liu F, Zhou ZH. Comparative virion structures of humanherpesviruses. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al, eds. Chapter 3. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
  7. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57(5):448-62. [Crossref]  [PubMed]  [PMC] 
  8. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect. 2001;77(4):232-7. [Crossref]  [PubMed]  [PMC] 
  9. Plotkin SA, Orestein WA, Offit PA, Edwards KM. 7th ed. Plotkin's Vaccines. Chapter 28. Amsterdam: Elsevier; 2017.
  10. Karasneh GA, Shukla D. Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J. 2011;8:481. [Crossref]  [PubMed]  [PMC] 
  11. Cooper RS, Georgieva ER, Borbat PP, Freed JH, Heldwein EE. Structural basis for membrane anchoring and fusion regulation of the herpes simplex virus fusogen gB. Nat Struct Mol Biol. 2018;25(5):416-24. [Crossref]  [PubMed]  [PMC] 
  12. Gianni T, Salvioli S, Chesnokova LS, Hutt-Fletcher LM, Campadelli-Fiume G. αvβ6- and αvβ8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion. PLoS Pathog. 2013;9(12):e1003806. [Crossref]  [PubMed]  [PMC] 
  13. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion and entry: a story with many characters. Viruses. 2012;4(5):800-32. [Crossref]  [PubMed]  [PMC] 
  14. Fontana J, Atanasiu D, Saw WT, Gallagher JR, Cox RG, Whitbeck JC, et al. The fusion loops of the initial prefusion conformation of herpes simplex virus 1 fusion protein point toward the membrane. mBio. 2017;8(4):e01268-17. [Crossref]  [PubMed]  [PMC] 
  15. Weed DJ, Nicola AV. Herpes simplex virus membrane fusion. Adv Anat Embryol Cell Biol. 2017;223:29-47. [Crossref]  [PubMed]  [PMC] 
  16. Xu X, Zhang Y, Li Q. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. Rev Med Virol. 2019;29(4):e2054. [Crossref]  [PubMed]  [PMC] 
  17. Koelle DM. Immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
  18. Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T. Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol. 2012;2(1):28-36. [Crossref]  [PubMed] 
  19. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol. 2008;6(3):211-21. [Crossref]  [PubMed] 
  20. Smith G. Herpesvirus transport to the nervous system and back again. Annu Rev Microbiol. 2012;66:153-76. [Crossref]  [PubMed]  [PMC] 
  21. Kim HC, Lee HK. Vaccines against genital herpes: where are we? Vaccines (Basel). 2020;8(3):420. [Crossref]  [PubMed]  [PMC] 
  22. Amin I, Younas S, Afzal S, Shahid M, Idrees M. Herpes simplex virus type 1 and host antiviral immune responses: an update. Viral Immunol. 2019;32(10):424-9. [Crossref]  [PubMed] 
  23. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4(5):491-6. [Crossref]  [PubMed] 
  24. Melchjorsen J, Matikainen S, Paludan SR. Activation and evasion of innate antiviral immunity by herpes simplex virus. Viruses. 2009;1(3):737-59. [Crossref]  [PubMed]  [PMC] 
  25. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32:461-88. [Crossref]  [PubMed] 
  26. Hook LM, Awasthi S, Dubin J, Flechtner J, Long D, Friedman HM. A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection. Vaccine. 2019;37(4):664-9. [Crossref]  [PubMed]  [PMC] 
  27. Koujah L, Suryawanshi RK, Shukla D. Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea. Cell Mol Life Sci. 2019;76(3):405-19. [Crossref]  [PubMed]  [PMC] 
  28. Lobo AM, Agelidis AM, Shukla D. Pathogenesis of herpes simplex keratitis: the host cell response and ocular surface sequelae to infection and inflammation. Ocul Surf. 2019;17(1):40-9. [Crossref]  [PubMed]  [PMC] 
  29. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303-16. [Crossref]  [PubMed]  [PMC] 
  30. Agelidis AM, Shukla D. Cell entry mechanisms of HSV: what we have learned in recent years. Future Virol. 2015;10(10):1145-54. [Crossref]  [PubMed]  [PMC] 
  31. Bruno E, Pillus D, Cheng D, Vilke G, Pokrajac N. During the emergency department evaluation of a well-appearing neonate with fever, should empiric acyclovir be initiated? J Emerg Med. 2018;54(2):261-5. [Crossref]  [PubMed] 
  32. Green J. Psychosocial issues in genital herpes management. Herpes. 2004;11(3):60-2. [PubMed] 
  33. Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer's disease: a nested case-control study. Alzheimers Dement. 2015;11(6):587-92. [Crossref]  [PubMed] 
  34. Li Puma DD, Piacentini R, Leone L, Gironi K, Marcocci ME, De Chiara G, et al. Herpes Simplex virus type-1 infection ımpairs adult hippocampal neurogenesis via amyloid-β protein accumulation. Stem Cells. 2019;37(11):1467-80. [Crossref]  [PubMed] 
  35. Linard M, Letenneur L, Garrigue I, Doize A, Dartigues JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimers Dement. 2020;16(1):200-8. [Crossref]  [PubMed] 
  36. Johnston C, Morrow RA, Stanberry LR. Human herpesviruses: herpes simplex viruses types 1 and 2. In: Kaslow RA, Stanberry LR, LeDuc JW, eds. Viral Infections of Humans: Epidemiology and Control. 5th ed. New York, NY: Springer; 2014. p.829-54. [Crossref] 
  37. Looker KJ, Garnett GP. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect. 2005;81(2):103-7. [Crossref]  [PubMed]  [PMC] 
  38. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186 Suppl 1:S3-28. [Crossref]  [PubMed] 
  39. Ike AC, Onu CJ, Ononugbo CM, Reward EE, Muo SO. Immune response to herpes simplex virus infection and vaccine development. Vaccines (Basel). 2020;8(2):302. [Crossref]  [PubMed]  [PMC] 
  40. Rafferty E, McDonald W, Qian W, Osgood ND, Doroshenko A. Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling. PeerJ. 2018;6:e5012. [Crossref]  [PubMed]  [PMC] 
  41. Bernstein DI, Flechtner JB, McNeil LK, Heineman T, Oliphant T, Tasker S, et al; Genocea study group. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine. 2019;37(26):3443-50. [Crossref]  [PubMed] 
  42. Awasthi S, Hook LM, Shaw CE, Friedman HM. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. Hum Vaccin Immunother. 2017;13(12):2785-93. [Crossref]  [PubMed]  [PMC] 
  43. Khodai T, Chappell D, Christy C, Cockle P, Eyles J, Hammond D, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol. 2011;18(10):1702-9. [Crossref]  [PubMed]  [PMC] 
  44. Mundle ST, Hernandez H, Hamberger J, Catalan J, Zhou C, Stegalkina S, et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS One. 2013;8(2):e57224. [Crossref]  [PubMed]  [PMC] 
  45. Srivastava R, Roy S, Coulon PG, Vahed H, Prakash S, Dhanushkodi N, et al. Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4+ and CD8+ TRM cells associated with protection against recurrent genital herpes. J Virol. 2019;93(9):e02309-18. [Crossref]  [PubMed]  [PMC] 
  46. Whitley R, Baines J. Clinical management of herpes simplex virus infections: past, present, and future. F1000Res. 2018;7:F1000 Faculty Rev-1726. [Crossref]  [PubMed]  [PMC] 
  47. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016;34(26):2948-52. [Crossref]  [PubMed] 
  48. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999;282(4):331-40. [Crossref]  [PubMed] 
  49. Stanfield BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied AA, et al. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS One. 2014;9(10):e109890. [Crossref]  [PubMed]  [PMC] 
  50. Awasthi S, Hook LM, Shaw CE, Pahar B, Stagray JA, Liu D, et al. An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs. PLoS Pathog. 2017;13(1):e1006141. [Crossref]  [PubMed]  [PMC] 
  51. Egan KP, Hook LM, Naughton A, Pardi N, Awasthi S, Cohen GH, et al. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathog. 2020;16(7):e1008795. [Crossref]  [PubMed]  [PMC] 
  52. Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, et al. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol. 2014;88(21):12612-22. [Crossref]  [PubMed]  [PMC] 
  53. LeRoux-Roels G, Moreau E, Desombere I. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex 9gD2t) candidate vaccine with MPL. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; Orlando USA; 4-7 October; 1994.
  54. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al; Herpevac trial for women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366(1):34-43. [Crossref]  [PubMed]  [PMC] 
  55. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615-7. [Crossref]  [PubMed]  [PMC] 
  56. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis. 2000;30(3):549-66. [Crossref]  [PubMed] 
  57. Awasthi S, Huang J, Shaw C, Friedman HM. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. J Virol. 2014;88(15):8421-32. [Crossref]  [PubMed]  [PMC] 
  58. Petro C, González PA, Cheshenko N, Jandl T, Khajoueinejad N, Bénard A, et al. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife. 2015;4:e06054. [Crossref]  [PubMed]  [PMC] 
  59. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol. 2004;11(3):437-45. [Crossref]  [PubMed]  [PMC] 
  60. Iyer AV, Pahar B, Chouljenko VN, Walker JD, Stanfield B, Kousoulas KG. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses. Virol J. 2013;10:317. [Crossref]  [PubMed]  [PMC] 
  61. Stanfield BA, Rider PJF, Caskey J, Del Piero F, Kousoulas KG. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. Vaccine. 2018;36(20):2842-9. [Crossref]  [PubMed] 
  62. Kim HC, Oh DS, Park JH, Kim HJ, Seo YB, Yoo HJ, et al. Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa. Antiviral Res. 2020;177:104755. [Crossref]  [PubMed] 
  63. Zhou Y, Wang Z, Xu Y, Zhang Z, Hua R, Liu W, et al. Optimized DNA vaccine enhanced by adjuvant IL28B induces protective immune responses against herpes simplex virus type 2 in mice. Viral Immunol. 2017;30(8):601-14. [Crossref]  [PubMed] 
  64. Ogasawara M, Suzutani T, Yoshida I, Azuma M. Role of the UL25 gene product in packaging DNA into the herpes simplex virus capsid: location of UL25 product in the capsid and demonstration that it binds DNA. J Virol. 2001;75(3):1427-36. [Crossref]  [PubMed]  [PMC] 
  65. Liu W, Zhou Y, Wang Z, Zhang Z, Wang Q, Su W, et al. Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice. Microbiol Immunol. 2017;61(5):176-84. [Crossref]  [PubMed] 
  66. Cunningham AL, Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes. 2001;8 Suppl 1:6A-10A. [PubMed] 
  67. Blank H, Haines HG. Experimental human reinfection with herpes simplex virus. J Invest Dermatol. 1973;61(4):223-5. [Crossref]  [PubMed] 
  68. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003;16(1):96-113. [Crossref]  [PubMed]  [PMC] 
  69. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012;491(7424):463-7. [Crossref]  [PubMed]  [PMC] 
  70. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol. 2011;85(7):3461-72. [Crossref]  [PubMed]  [PMC] 
  71. Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, et al. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol. 2011;85(9):4184-97. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com